Naringin protects against Bisphenol-A induced oculopathy as implication of cataract in hypertensive rat model

People who have experienced high blood pressure are at greater risk of susceptibility to other health problems including oculopathy. The patients with these experiences do not have adequate treatment and those who do; spend much funds on the drug purchase. The study examines the protective effect of...

Full description

Bibliographic Details
Main Authors: J.K. Akintunde, T.E. Akintola, M.O. Hammed, C.O. Amoo, A.M. Adegoke, L.O. Ajisafe
Format: Article
Language:English
Published: Elsevier 2020-06-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332220302341
id doaj-b8435ed958fd48dfa4eea5b31a2f9743
record_format Article
spelling doaj-b8435ed958fd48dfa4eea5b31a2f97432021-05-20T07:41:08ZengElsevierBiomedicine & Pharmacotherapy0753-33222020-06-01126110043Naringin protects against Bisphenol-A induced oculopathy as implication of cataract in hypertensive rat modelJ.K. Akintunde0T.E. Akintola1M.O. Hammed2C.O. Amoo3A.M. Adegoke4L.O. Ajisafe5Applied Biochemistry and Molecular Toxicology Research Group, Department of Biochemistry, College of Biosciences, Federal University of Agriculture, Abeokuta, Nigeria; Corresponding author.Applied Biochemistry and Molecular Toxicology Research Group, Department of Biochemistry, College of Biosciences, Federal University of Agriculture, Abeokuta, NigeriaApplied Biochemistry and Molecular Toxicology Research Group, Department of Biochemistry, College of Biosciences, Federal University of Agriculture, Abeokuta, NigeriaApplied Biochemistry and Molecular Toxicology Research Group, Department of Biochemistry, College of Biosciences, Federal University of Agriculture, Abeokuta, NigeriaCancer Research and Molecular Biology Laboratories, Department of Biochemistry, Faculty of Basic Medical Sciences, College of Medicine, University of Ibadan, NigeriaCancer Research and Molecular Biology Laboratories, Department of Biochemistry, Faculty of Basic Medical Sciences, College of Medicine, University of Ibadan, NigeriaPeople who have experienced high blood pressure are at greater risk of susceptibility to other health problems including oculopathy. The patients with these experiences do not have adequate treatment and those who do; spend much funds on the drug purchase. The study examines the protective effect of naringin (NRG) against ocular impairment in L-NAME induced hypertensive rat on exposure to a cellular disruptor. Fifty-six adult male albino rats were randomly distributed into eight (n = 7) groups. Group I: control animals, Group II was treated with Nω-nitro-L-arginine methyl ester hydrochloride (L-NAME), Group III was treated with 50 mg/kg Bisphenol-A, Group IV was treated with L-NAME +50 mg/kg Bisphenol-A. Group V was administered with L-NAME +80 mg/kg NRG. Group VI was administered with 50 Mg/kg BPA + 80 mg/kg NRG. Group VII was administered with L-NAME+50 mg/kg Bisphenol-A +80 mg/kg NRG. Lastly, group VIII was treated with 80 mg/kg NRG alone for 14 days. Naringin prevented hypertension and ocular dysfunction by depleting the activities of angiotensin-converting enzymes, arginase, aldose-reductase and phosphodiesterase-51 (PDE-51) with corresponding down-regulation of inflammatory markers including TNF-α and IL-B. Moreover, ocular impairment was remarkably reduced by NRG as manifested by the decreased activities of AChE, BuChE, MAO-A and enzymes of ATP hydrolysis (ATPase, ADPase, AMPase) and adenosine deaminase with resultant increased NO level. Also, ocular expression of CD43 transcript, caspaace-9 and tumor suppressor P53 proteins were suppressed on treatment with NRG. This study corroborates the view that NRG may be a useful therapy in alleviating inflammatory markers, apoptosis and metabolic nucleotides disorders via the NOS/cGMP/PKG signaling pathways in hypertensive rat model on exposure to a cellular disruptor.http://www.sciencedirect.com/science/article/pii/S0753332220302341NaringinOculopathyHypertensionNeurotransmittersATP hydrolysisCellular disruptor
collection DOAJ
language English
format Article
sources DOAJ
author J.K. Akintunde
T.E. Akintola
M.O. Hammed
C.O. Amoo
A.M. Adegoke
L.O. Ajisafe
spellingShingle J.K. Akintunde
T.E. Akintola
M.O. Hammed
C.O. Amoo
A.M. Adegoke
L.O. Ajisafe
Naringin protects against Bisphenol-A induced oculopathy as implication of cataract in hypertensive rat model
Biomedicine & Pharmacotherapy
Naringin
Oculopathy
Hypertension
Neurotransmitters
ATP hydrolysis
Cellular disruptor
author_facet J.K. Akintunde
T.E. Akintola
M.O. Hammed
C.O. Amoo
A.M. Adegoke
L.O. Ajisafe
author_sort J.K. Akintunde
title Naringin protects against Bisphenol-A induced oculopathy as implication of cataract in hypertensive rat model
title_short Naringin protects against Bisphenol-A induced oculopathy as implication of cataract in hypertensive rat model
title_full Naringin protects against Bisphenol-A induced oculopathy as implication of cataract in hypertensive rat model
title_fullStr Naringin protects against Bisphenol-A induced oculopathy as implication of cataract in hypertensive rat model
title_full_unstemmed Naringin protects against Bisphenol-A induced oculopathy as implication of cataract in hypertensive rat model
title_sort naringin protects against bisphenol-a induced oculopathy as implication of cataract in hypertensive rat model
publisher Elsevier
series Biomedicine & Pharmacotherapy
issn 0753-3322
publishDate 2020-06-01
description People who have experienced high blood pressure are at greater risk of susceptibility to other health problems including oculopathy. The patients with these experiences do not have adequate treatment and those who do; spend much funds on the drug purchase. The study examines the protective effect of naringin (NRG) against ocular impairment in L-NAME induced hypertensive rat on exposure to a cellular disruptor. Fifty-six adult male albino rats were randomly distributed into eight (n = 7) groups. Group I: control animals, Group II was treated with Nω-nitro-L-arginine methyl ester hydrochloride (L-NAME), Group III was treated with 50 mg/kg Bisphenol-A, Group IV was treated with L-NAME +50 mg/kg Bisphenol-A. Group V was administered with L-NAME +80 mg/kg NRG. Group VI was administered with 50 Mg/kg BPA + 80 mg/kg NRG. Group VII was administered with L-NAME+50 mg/kg Bisphenol-A +80 mg/kg NRG. Lastly, group VIII was treated with 80 mg/kg NRG alone for 14 days. Naringin prevented hypertension and ocular dysfunction by depleting the activities of angiotensin-converting enzymes, arginase, aldose-reductase and phosphodiesterase-51 (PDE-51) with corresponding down-regulation of inflammatory markers including TNF-α and IL-B. Moreover, ocular impairment was remarkably reduced by NRG as manifested by the decreased activities of AChE, BuChE, MAO-A and enzymes of ATP hydrolysis (ATPase, ADPase, AMPase) and adenosine deaminase with resultant increased NO level. Also, ocular expression of CD43 transcript, caspaace-9 and tumor suppressor P53 proteins were suppressed on treatment with NRG. This study corroborates the view that NRG may be a useful therapy in alleviating inflammatory markers, apoptosis and metabolic nucleotides disorders via the NOS/cGMP/PKG signaling pathways in hypertensive rat model on exposure to a cellular disruptor.
topic Naringin
Oculopathy
Hypertension
Neurotransmitters
ATP hydrolysis
Cellular disruptor
url http://www.sciencedirect.com/science/article/pii/S0753332220302341
work_keys_str_mv AT jkakintunde naringinprotectsagainstbisphenolainducedoculopathyasimplicationofcataractinhypertensiveratmodel
AT teakintola naringinprotectsagainstbisphenolainducedoculopathyasimplicationofcataractinhypertensiveratmodel
AT mohammed naringinprotectsagainstbisphenolainducedoculopathyasimplicationofcataractinhypertensiveratmodel
AT coamoo naringinprotectsagainstbisphenolainducedoculopathyasimplicationofcataractinhypertensiveratmodel
AT amadegoke naringinprotectsagainstbisphenolainducedoculopathyasimplicationofcataractinhypertensiveratmodel
AT loajisafe naringinprotectsagainstbisphenolainducedoculopathyasimplicationofcataractinhypertensiveratmodel
_version_ 1721435028624244736